Ambrilia Biopharma develops one-month formulation of goserelin

The company has already developed a proprietary, three-month formulation of goserelin for which a Phase I/II clinical program in prostate cancer patients was initiated in July 2008.

Ambrilia’s goserelin formulations are indicated for hormone-sensitive prostate cancer and several gynecological indications such as fibro-myomas and endometriosis. They are also said to be injectable depot formulations. The goserelin formulations are manufactured by Ambrilia at its GMP (good manufacturing practice) facilities in Montreal.

Philippe Calais, president and CEO of Ambrilia Biopharma, said: “With the addition of a one-month goserelin formulation we now offer to interested acquirers a complete generic Zoladex package which includes a potentially first-to-market three-month generic version.

“This further enhances the value of our goserelin product offering focused on European market and maximizes potential deal terms. All efforts are being made in order to conclude an agreement by the end of 2008.”